We are live on ! Find out more
HQL

abrdn Life Sciences Investors

67 hedge funds and large institutions have $74.4M invested in abrdn Life Sciences Investors in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0% more funds holding

Funds holding: 6767 (0)

0.84% less ownership

Funds ownership: 16.8%15.96% (-0.84%)

13% less capital invested

Capital invested by funds: $85.1M → $74.4M (-$10.7M)

Holders
67
Holders Change
Holders Change %
0%
% of All Funds
1.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
30
Reduced
14
Closed
10
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q4 2021 in Review

67 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2021, worth a combined $74.4M — down 13% from $85.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new HQL positions and 10 closed out — a net gain of 1 holder — while 30 added to existing stakes and 14 trimmed.

The largest buyer was LPL Financial, adding an estimated $1.22M. The largest seller was Advisors Asset Management, cutting an estimated $1.46M.

  • 67 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $74.4M of abrdn Life Sciences Investors stock for Q4 2021, down 13% quarter-over-quarter.
  • 11 funds opened new abrdn Life Sciences Investors positions in Q4 2021 and 10 closed out, a net change of +1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q4 2021 was LPL Financial, an estimated $1.22M added.
  • The largest abrdn Life Sciences Investors seller in Q4 2021 was Advisors Asset Management, an estimated $1.46M sold.

Based on aggregated 13F filings for Q4 2021.